News

Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.

 

Feedlot Safety Study with Amplimune® Published in the Australian Veterinary Journal

A paper has been published in the Australian Veterinary Journal, “The innate immune stimulant Amplimune® is safe to administer to young feedlot cattle”, summarizing a research study conducted by CSIRO.

MCWF (Amplimune) Significantly Improves Fertility and Decreases Clinical Mastitis and Metritis in Organic-Certified Dairy Herd

In a newly published study, the incidence rates of both clinical mastitis and metritis before 28 days in milk were lower, and pregnancy rates (3 time points) were higher in Amplimune-treated cows vs. placebo-treated controls.

Amplimune® Now Available in New Zealand

NovaVive's immunotherapy for calf scours - Amplimune® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.

3 calves in a field

MCWF Greatly Improves Pregnancy Success in Heifer Embryo Transfer Recipients

An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.

Holstein calf looking at camera

Amplimune® Receives Regulatory Approval in New Zealand

NovaVive's immunotherapy for calf scours - Amplimune® - has received approval for sale in New Zealand by Agricultural Compounds and Veterinary Medicines (ACVM). NovaVive has appointed Agilis Vet Ltd as its NZ distributor.

close-up of Bernese Mountain Dog

NovaVive Seeking to Enhance Quality of Life of Dogs with Cancer

Immunocidin is being evaluated in a clinical study as a palliative therapy for dogs with malignant cancer. The goal is to increase the dogs' comfort and maintain or improve the quality and duration of their remaining life.

Sign up to stay up-to-date with NovaVive news.